BioCentury | Oct 12, 2015
Company News

Lipid Therapeutics, Nestle deal

...disclose financial terms, and Nestle did not respond to inquiries (see BioCentury, March 12, 2012). Lipid Therapeutics GmbH...
BioCentury | Nov 17, 2014
Clinical News

LT-02: Phase III started

...European Phase III PROTECT-2 trial. The start of PROTECT-1 triggered an undisclosed milestone payment to Lipid Therapeutics...
...2009 deal granting Dr. Falk European rights to co-develop LT-02 (see BioCentury, March 12, 2012). Lipid Therapeutics GmbH...
BioCentury | Mar 12, 2012
Company News

Lipid Therapeutics, Dr. Falk Pharma deal

...exercised an option to license European rights to ulcerative colitis (UC) product LT-02 from Lipid Therapeutics. Lipid Therapeutics...
...lower gut. Lipid said it is in discussions with potential development partners in the U.S. Lipid Therapeutics GmbH...
BioCentury | Mar 8, 2012
Company News

Dr. Falk exercises option for Lipid's UC product

...option to license European rights to ulcerative colitis (UC) product LT-02 from Lipid Therapeutics GmbH (Heidelberg, Germany). Lipid Therapeutics...
BioCentury | Jun 27, 2011
Clinical News

LT-02: Phase IIb data

...data will be presented at the United European Gastroenterology Week meeting in Stockholm in October. Lipid Therapeutics...
...after which it has an option to license European rights to develop and commercialize LT-02. Lipid Therapeutics GmbH...
BioCentury | Jun 22, 2011
Clinical News

High-dose LT-02 meets ulcerative colitis endpoint

Lipid Therapeutics GmbH (Heidelberg, Germany) said high-dose LT-02 given four times per day met the primary endpoint in a Phase IIb trial to treat mesalazine-refractory ulcerative colitis. A 0.8 g dose of LT-02 significantly reduced...
BioCentury | Feb 8, 2010
Clinical News

LT-02: Phase IIb started

...evaluate LT-02 for 12 weeks, with a follow-up observation period of up to 8 weeks. Lipid Therapeutics...
...granted Dr. Falk Pharma European rights to co-develop LT-02 through Phase IIb testing last year. Lipid Therapeutics GmbH...
Items per page:
1 - 7 of 7
BioCentury | Oct 12, 2015
Company News

Lipid Therapeutics, Nestle deal

...disclose financial terms, and Nestle did not respond to inquiries (see BioCentury, March 12, 2012). Lipid Therapeutics GmbH...
BioCentury | Nov 17, 2014
Clinical News

LT-02: Phase III started

...European Phase III PROTECT-2 trial. The start of PROTECT-1 triggered an undisclosed milestone payment to Lipid Therapeutics...
...2009 deal granting Dr. Falk European rights to co-develop LT-02 (see BioCentury, March 12, 2012). Lipid Therapeutics GmbH...
BioCentury | Mar 12, 2012
Company News

Lipid Therapeutics, Dr. Falk Pharma deal

...exercised an option to license European rights to ulcerative colitis (UC) product LT-02 from Lipid Therapeutics. Lipid Therapeutics...
...lower gut. Lipid said it is in discussions with potential development partners in the U.S. Lipid Therapeutics GmbH...
BioCentury | Mar 8, 2012
Company News

Dr. Falk exercises option for Lipid's UC product

...option to license European rights to ulcerative colitis (UC) product LT-02 from Lipid Therapeutics GmbH (Heidelberg, Germany). Lipid Therapeutics...
BioCentury | Jun 27, 2011
Clinical News

LT-02: Phase IIb data

...data will be presented at the United European Gastroenterology Week meeting in Stockholm in October. Lipid Therapeutics...
...after which it has an option to license European rights to develop and commercialize LT-02. Lipid Therapeutics GmbH...
BioCentury | Jun 22, 2011
Clinical News

High-dose LT-02 meets ulcerative colitis endpoint

Lipid Therapeutics GmbH (Heidelberg, Germany) said high-dose LT-02 given four times per day met the primary endpoint in a Phase IIb trial to treat mesalazine-refractory ulcerative colitis. A 0.8 g dose of LT-02 significantly reduced...
BioCentury | Feb 8, 2010
Clinical News

LT-02: Phase IIb started

...evaluate LT-02 for 12 weeks, with a follow-up observation period of up to 8 weeks. Lipid Therapeutics...
...granted Dr. Falk Pharma European rights to co-develop LT-02 through Phase IIb testing last year. Lipid Therapeutics GmbH...
Items per page:
1 - 7 of 7